Hyperlipidemia
Conditions
Keywords
Hyperlipidemia, berberine, lipoprotein, lipid, sex-hormones, apoA1, apoB, Lp(a)
Brief summary
The goal of this clinical trial is to learn if berberine works to affect lipids and lipoproteins in Chinese females aged 20 to 65 years with hyperlipidaemia. The goal also includes to examine the sex-specific effect of berberine on lipids and lipoproteins. Our previous HMRF-funded randomized trial in men and prior evidence suggests berberine affects sex hormones. Given the different sex hormone profiles in men and women, the main question it aims to answer is: • Does berberine have sex-specific lipid-modifying effects? Researchers will compare berberine to a placebo (a look-alike substance that contains no drug) to see if berberine works to affect lipids and lipoproteins. Participants will: * Take a baseline questionnaire * Take berberine or a placebo every day for 12 weeks * Take follow-up visits after 8 weeks and 12 weeks for blood sample collections and tests
Detailed description
The overall aim of the project is to assess the sex-specific effects of berberine on lipids, apoA1, apoB, and Lp(a). Specifically, the objectives of the project are to 1) assess the effect of berberine on lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol, non-HDL cholesterol, and TG), lipoproteins (apoA1, apoB, and Lp(a)) and sex hormones by conducting a randomized, parallel, double-masked, placebo-controlled trial of berberine RCT in women; 2) assess the effect of berberine on apoA1, apoB, Lp(a) and sex hormone binding globulin (SHBG) in men using stored samples from our completed RCT of berberine in men; 3) assess whether the effects of berberine on lipids, lipoproteins and sex hormones differ in men and women. This is a randomized, parallel, double-blinded, placebo-controlled trial of berberine in 100 Chinese women with hyperlipidemia in Hong Kong. Participants will be randomized to two arms in which half of the participants will receive berberine (500 mg orally twice a day) and the other half will receive placebos (500 mg orally twice a day) for 12 weeks. Blood samples will be taken at baseline, 8-week and 12-week intervention. The investigators will use an intention-to-treat analysis. Changes in lipids and lipoproteins after 8- and 12-week treatment will be assessed using analysis of variance and generalized estimating equation (GEE) model accounting for measurements at both time points.
Interventions
DRUGBerberine
Participants will take purified berberine (500 mg orally twice a day) for 12 weeks.
DRUGPlacebo
Participants will take placebo tablets, a look-alike substance that contains no drug, (500 mg orally twice a day) for 12 weeks.
Sponsors
The University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Women, who are: 1. aged 20 to 65 years. 2. of Chinese ethnicity. 3. with hyperlipidemia, defined as TG greater than 150 mg/dl (1.70 mmol/L), total cholesterol greater than 200 mg/dl (5.16 mmol/L), and/or LDL-cholesterol greater than 100 mg/dl (2.58 mmol/L). 4. willing to make return visits. 5. not currently receiving hormone replacement therapy or medications/pills containing hormones (such as hormonal contraception or hormone replacement therapy) in the past 12 months. 6. not currently taking berberine or nutraceuticals that contain berberine. 7. free of any congenital diseases, including familial hypercholesterolemia. 8. free of Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. G6PD will be tested using G6PD rapid diagnostic tests. 9. free of hemolytic anemia. 10. free of any infectious diseases, e.g., seasonal influenza. 11. without liver/renal diseases. 12. not pregnant or planning to get pregnant in the next three months. Pregnancy will be ruled out using HCG ULTRA pregnancy tests. 13. not currently breastfeeding.
Exclusion criteria
* All men, and women who did not meet the aforementioned inclusion criteria and/or were unable or unwilling to provide consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total cholesterol in mmol/L | 4 months for biomarker assessment, 6 months for data analysis | Total cholesterol, LDL-cholesterol, TG, apoB, and Lp(a), which are causal factors for coronary heart disease. |
| LDL-cholesterol in mmol/L | 4 months for biomarker assessment, 6 months for data analysis | Total cholesterol, LDL-cholesterol, TG, apoB, and Lp(a), which are causal factors for coronary heart disease. |
| Triglycerides in mmol/L | 4 months for biomarker assessment, 6 months for data analysis | Total cholesterol, LDL-cholesterol, TG, apoB, and Lp(a), which are causal factors for coronary heart disease. |
| Apolipoprotein B in mg/dL | 4 months for biomarker assessment, 6 months for data analysis | Total cholesterol, LDL-cholesterol, TG, apoB, and Lp(a), which are causal factors for coronary heart disease. |
| Lipoprotein (a) in mg/dL | 4 months for biomarker assessment, 6 months for data analysis | Total cholesterol, LDL-cholesterol, TG, apoB, and Lp(a), which are causal factors for coronary heart disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HDL-cholesterol in mmol/L | 4 months for biomarker assessment, 6 months for data analysis | Other relevant lipids and lipoproteins. |
| Testosterone in ng/dL | 4 months for biomarker assessment, 6 months for data analysis | Examine the sex-specific effects of berberine on apoA1, apoB, Lp(a) and lipids |
| Non-HDL-cholesterol in mmol/L | 4 months for biomarker assessment, 6 months for data analysis | Other relevant lipids and lipoproteins.as liver and kidney function. |
| Apolipoprotein A1 in mg/dL | 4 months for biomarker assessment, 6 months for data analysis | Other relevant lipids and lipoproteins. |
| Estradiol (E2) in pg/mL | 4 months for biomarker assessment, 6 months for data analysis | Examine the sex-specific effects of berberine on apoA1, apoB, Lp(a) and lipids |
| Sex hormone binding globulin (SHBG) in nmol/L | 4 months for biomarker assessment, 6 months for data analysis | Examine the sex-specific effects of berberine on apoA1, apoB, Lp(a) and lipids |
Countries
Hong Kong
Outcome results
None listed